Our Pricing

Mounjaro vs Wegovy: Expert UK Pharmacy Comparison

When considering a mounjaro vs wegovy uk comparison, understanding the clinical differences between tirzepatide and semaglutide is essential for making an informed choice. At Cured Pharmacy, our UK-registered clinical team assesses your medical history to determine which treatment may be most suitable, with transparent pricing from £135.00 and discreet nationwide delivery.

How Mounjaro and Wegovy Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. This dual-action mechanism distinguishes it from Wegovy, which contains semaglutide—a single GLP-1 receptor agonist. Both medications mimic natural hormones that regulate appetite and blood sugar, but tirzepatide's additional GIP pathway may produce enhanced metabolic effects in certain patients [1].

Wegovy works by activating GLP-1 receptors in the brain and pancreas, slowing gastric emptying and reducing appetite [2]. Clinical trials demonstrate that semaglutide produces significant weight reduction when combined with lifestyle modification, making it an established option for UK patients seeking prescription weight management support [2].

The dual-receptor activation in Mounjaro may explain why SURPASS-3 trial participants achieved an average 22.5% body weight reduction over 72 weeks at the highest dose, compared to 14.9% with semaglutide in the STEP 1 trial [1][2]. However, individual responses vary, and your UK prescriber will consider your medical history, BMI, and any contraindications when recommending treatment.

Clinical Efficacy: Mounjaro vs Wegovy UK Trial Data

In the SURMOUNT-1 trial involving 2,539 adults with obesity, tirzepatide demonstrated dose-dependent weight loss, with participants on the 15mg dose losing an average of 22.5% of their body weight over 72 weeks [1]. This represents one of the highest efficacy rates observed in any obesity medication trial to date.

Wegovy's pivotal STEP 1 trial enrolled 1,961 adults and reported an average weight loss of 14.9% over 68 weeks with the 2.4mg weekly dose [2]. Approximately 86.4% of participants achieved at least 5% weight loss, and 50.5% achieved at least 15% weight loss—outcomes that significantly exceeded placebo groups [2].

Both medications require adherence to a reduced-calorie diet and increased physical activity to achieve optimal results. UK prescribers typically initiate treatment at lower doses and gradually titrate upward to minimise gastrointestinal side effects whilst allowing your body to adjust to the medication [3].

Long-Term Weight Maintenance

Clinical evidence suggests that continued treatment is necessary to maintain weight loss with both tirzepatide and semaglutide [1][2]. In withdrawal studies, participants who discontinued medication regained a significant portion of lost weight within one year, highlighting the importance of viewing these treatments as long-term management tools rather than short-term solutions [4].

Dosing Schedules and Administration

Both Mounjaro and Wegovy are administered as once-weekly subcutaneous injections using pre-filled pens. Mounjaro dosing begins at 2.5mg weekly for four weeks, then increases to 5mg. Your prescriber may further titrate to 7.5mg, 10mg, 12.5mg, or 15mg based on your response and tolerability [1].

Wegovy follows a different escalation schedule, starting at 0.25mg weekly and increasing monthly through 0.5mg, 1mg, and 1.7mg before reaching the maintenance dose of 2.4mg [2]. This gradual titration helps reduce the incidence of nausea and other gastrointestinal effects commonly reported during initial treatment.

The KwikPen devices used for Mounjaro and the pre-filled pens for Wegovy are designed for self-administration at home. Your UK prescriber will provide detailed injection technique guidance, and our pharmacy team at Cured Pharmacy supplies written instructions with every dispensed medication. Injections can be given in the abdomen, thigh, or upper arm, and the injection site should be rotated weekly to prevent lipodystrophy [3].

Side Effects and Safety Considerations

The most commonly reported side effects with both tirzepatide and semaglutide are gastrointestinal in nature, including nausea, vomiting, diarrhoea, constipation, and abdominal discomfort [1][2]. These effects are typically most pronounced during dose escalation and tend to diminish as treatment continues.

In clinical trials, approximately 44% of Mounjaro participants experienced nausea at some point during treatment, compared to 44% with Wegovy [1][2]. Severe gastrointestinal events leading to treatment discontinuation occurred in approximately 4-6% of participants across both medications. Starting at the lowest dose and following the prescribed titration schedule significantly reduces the risk of intolerable side effects [3].

Both medications carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans [1][2]. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your UK prescriber will screen for these conditions during your clinical assessment.

Who Should Not Use These Medications

Mounjaro and Wegovy are not suitable for individuals with type 1 diabetes, a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy [1][2]. Pregnant or breastfeeding women should not use these medications, and treatment should be discontinued at least two months before planned conception due to the long half-life of these drugs [3]. Always disclose your complete medical history during your online consultation at Cured Pharmacy.

Cost and Availability in the UK

At Cured Pharmacy, Mounjaro is available with transparent upfront pricing, whilst Wegovy starts from competitive rates that are lower than typical market pricing. Both medications require a valid UK prescription following clinical assessment by our registered prescribers, and prices include the medication, clinical consultation, and discreet delivery to your UK address.

Supply availability for both treatments has improved significantly since initial licensing, though occasional stock fluctuations may occur due to high demand across UK pharmacies. Our team monitors stock levels daily and will inform you of any anticipated delays during your consultation process.

Many UK patients find that the clinical benefits and convenience of once-weekly injections justify the investment in prescription weight management. Unlike over-the-counter options, GLP-1 receptor agonists address the underlying hormonal mechanisms of appetite regulation and have demonstrated sustained efficacy in peer-reviewed clinical trials [1][2].

Choosing Between Mounjaro and Wegovy

The decision between tirzepatide and semaglutide should be guided by your UK prescriber based on your BMI, weight loss goals, medical history, and any existing conditions such as type 2 diabetes. Mounjaro's dual-receptor mechanism may offer advantages for patients requiring maximal weight reduction, whilst Wegovy's established safety profile and extensive real-world use data make it a trusted first-line option [1][2].

Cost considerations, injection frequency preferences, and individual tolerability also influence treatment selection. Both medications require the same once-weekly administration schedule, so the primary differences lie in their mechanism of action, clinical trial outcomes, and pricing structure.

At Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team provide personalised recommendations during your free online consultation. We review your health questionnaire, assess contraindications, and ensure you understand proper administration technique and expected outcomes before any prescription is issued. All consultations are conducted by UK-registered prescribers in compliance with MHRA and GPhC guidelines.

Starting Your Treatment Journey

Beginning treatment with either Mounjaro or Wegovy requires commitment to lifestyle modification alongside medication. Clinical trials demonstrating significant weight loss included participants who followed reduced-calorie diets and increased physical activity [1][2]. Your prescriber may recommend keeping a food diary, setting realistic weekly weight loss targets of 0.5-1kg, and scheduling follow-up assessments to monitor progress and adjust dosing as needed.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to lifestyle modifications alongside medication use.